An Ancillary Study Protocol to GlaxoSmithKline Phase IIb RTS,S/AS01E Malaria Vaccine Trial (Study Number 204889 [MALARIA-094]) Entitled, "Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age"
Latest Information Update: 26 Feb 2024
At a glance
- Drugs GSK 257049 (Primary) ; Rabies vaccine
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 23 Jun 2022 Planned End Date changed from 30 Jun 2023 to 29 Jun 2023.
- 23 Jun 2022 Planned primary completion date changed from 30 Jun 2023 to 29 Jun 2023.
- 23 Jun 2022 Status changed from not yet recruiting to active, no longer recruiting.